Patient-centered, actionable pathology interpretation for molecular diagnostics. Real pathologists reviewing every result, translating resistance genes into treatment guidance your providers can use. No generic reports. No black-box algorithms.
A molecular panel returns a list of pathogens and resistance markers. The provider sees the report, sees the acronyms, and reaches for the broad-spectrum antibiotic that has always worked before.
Resistance gene interpretation means patients get effective treatment from day one, not after the first antibiotic fails. Every consultation AICC delivers recommends the narrowest effective spectrum, because antimicrobial stewardship is the standard of care.
A board-certified pathologist reviews every case and translates what the result actually means: which organisms matter, which resistance markers cluster together, and which therapy the evidence supports. It returns into your existing workflow, under your laboratory's brand.
When providers understand the results the first time, they don't call your lab asking what it means.
AICC integrates with your existing workflow. The moment a complex molecular result is released, it arrives with our pathology team without re-keying or any parallel process for your staff to manage.
Quiet integrationA board-certified pathologist evaluates the complete result. Pathogens identified, resistance markers detected, what they mean together, and which antibiotics still work. Not spot-checked. Not sampled. Every single case.
Specialist judgmentCurrent IDSA guidance and antimicrobial stewardship principles distilled into recommendations providers can act on today. Not literature reviews they will never read. The pathologist signs the consultation, and that signature is what makes it clinically defensible.
Narrowest effective spectrumThe signed consultation reaches the ordering provider as part of your laboratory's report. Your branding. Your provider relationship. AICC stays the quiet specialist that made the consultation possible.
White label by designA board-certified pathologist reviews every consultation. Not spot-checked. Not sampled. Every single one, because that is what defensible medicine requires and what your providers expect when they read your name on a report.
Every consultation recommends the narrowest effective therapy the evidence supports. Patients get effective treatment from day one, not after the first antibiotic fails. Stewardship is not a feature. It is the standard of care.
Questions about a case? A real pathologist picks up. Not a call center. Not a chatbot. Complex cases deserve real conversations, and providers remember which laboratories make those conversations possible.
The difference is night and day. Before, I'd get a list of organisms and resistance genes and have to figure out what it meant. Now I get a clear recommendation I can act on, and when I have questions, an actual pathologist calls me back. That's what patient care should look like.
Pathologist-signed consultation reports under your brand. Clinical guidance providers can act on, not raw data they have to puzzle through. The kind of service that wins providers and keeps them.
For labs → / for biopharma and CROsConsistent, pathologist-validated biomarker interpretation across study sites. Operational rigor built for the timelines and audit expectations of regulated clinical work.
For research → / for health systemsPathology consultation services scaled to your enterprise needs. One partner, one contract, and the operational discipline to support a system of providers and patients at volume.
For enterprise →